Lead Sponsor

MoonLake Immunotherapeutics AG

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

No

•Participants who have completed a parental study (M1095-HS-301 or M1095-HS-302 \[adult studies\] or M1095-HS-304 \[adolescent study\]) and are eligible to continue to receive sonelokimab at the time of completing the parental study.
•Female participants are eligible to participate if they are not pregnant or breastfeeding
•Male participants must be willing to use a condom when sexually active with a partner of childbearing potential . Male participants must also agree to refrain from donating sperm during the study and for at least 8 weeks after the last dose of study treatment.

•Participants who meet any of the discontinuation criteria of the parental study at the time of enrollment in this OLE study.
•Participants who have ongoing or planned to use one or more of the prohibited HS or non-HS treatments specified in the protocol.
•Participants who plan to participate in another interventional study for a drug or device during this study.

Related studies

NCT03967600 · Hidradenitis Suppurativa

NCT06959225 · Hidradenitis Suppurativa

NCT06958211 · Hidradenitis Suppurativa

NCT07049575 · Hidradenitis Suppurativa

NCT06921850 · Hidradenitis Suppurativa

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa